Preclinical projects Please note: This page is currently being created and is being updated regularly - please bear with us - thank you It is thought that the presence of alpha-synuclein protein clumps in nerve endings in the brain is an early event in the development of Parkinson’s (PD). The presence of these clumps is associated with a reduction in the release of dopamine from the nerve cells (neurons) and this causes an alteration in communication between neurons - reflected in the development of symptoms of Parkinson's. Understanding brain insulin resistance and Parkinson’s - Dr Konrad Talbot, Cedar Sinai Hospital US - There is evidence that many early factors in PD, including alpha-synuclein clumping, can induce brain insulin resistance, which can in turn cause or exacerbate many other aspects of the disorder. This might explain why a clinical trial of an anti-diabetic drug known to reduce brain insulin resistance (exendin-4) produced evidence not only of symptomatic relief, but of slowing disease progression. Given the urgency of finding ways to slow what is today the inexorable decline of patients with PD into disability, the proposal study addresses issues related to the role of brain insulin resistance in PD and preclinical issues in choice of anti-diabetics in treating it. Newer members of this drug class have been found to be more effective than exendin-4 in reducing brain insulin resistance. Dr Talbot is testing the magnitude of brain insulin resistance in PD, to determine which anti-diabetics are most effective in reducing insulin resistance, and to identify likely causes. Testing the neuroprotective effects of novel long-lasting incretin hormone analogues in models of Parkinson’s - Christian Holscher, Lancaster University - Drugs originally developed as treatments for type 2 diabetes have been shown to have protective properties in the brain in several animal models of disease. In animal models of PD, exendin-4, has shown impressive protective effects, and a recent clinical trial (CPT funded research) that tested this drug in patients with PD also found very promising protective effects. Professor Holscher and colleagues have now developed a range of novel drugs that have superior properties compared with exendin-4. They are longer lasting and do not induce an immune response in the way exendin-4 does - these drugs are modelled on human gut hormones. Exendin-4 also has the disadvantage of lasting only a few hours in the blood stream. The new peptide drugs have been tested in a range of neurotoxicity assays and have shown powerful effects. In addition, Professor Holscher has tested a novel long-lasting peptide drug that has been developed by Professor Stephen Bloom as a new treatment for diabetes. This drug showed impressive neuroprotective effects in a pilot study. Professor Holscher has tested several of these new drugs in standard models of PD, in comparison with exendin-4 to assess whether the novel drugs have superior neuroprotective properties. Nurturing growth factors with Nurr1- Professor Anders Bjorklund, Lund University, Sweden - Nurr1 was originally discovered as an important growth factor in brain development that differentiated and promoted successful growth of midbrain dopamine neurones. However, recent studies, funded by CPT, have show that Nurr1 plays an important role in the adult brain too and there is evidence that impaired Nurr1 in neurones is a feature of Parkinson's (PD). There is also a correlation between too little Nurr1 production and too much of the toxic alpha-synuclein which spreads throughout neurons in PD, which in turn blocks the naturally occurring growth hormone GDNF in the brain. The goal of this project is to test a new orally available Nurr1 activating drug (an agonist) to see if it is neuroprotective and disease modifying in models of PD. Stopping dopamine neuron degeneration by preventing Alpha-synuclein redistribution at the synapses - Professor Maria Spillantini, Cambrige University - Professor Spillantini and the team at Cambridge believe that reducing the clumps and restoring normal distribution of alpha-synuclein in nerve endings will restore normal release of dopamine and therefore normal communication between the neurons, thereby reducing the clinical symptoms of Parkinson’s. This project follows on from an earlier study funded by CPT and proposes to test whether neuronal dysfunction in Parkinson’s disease initiates at the synapse where alpha-synuclein forms toxic aggregates. Two compounds will be introduced to determine whether they are able to restore communication between nerve cells and in doing so possibly indicate a new therapeutic target for a cure. Mitochondria are organelles which are found in every cell of the human body except red blood cells and they convert the energy of food molecules into the ATP which is used to power most cell functions. If mitochondria become diseased, they cannot carry out their critical function. Many diseases of aging are caused by defects in mitochondrial function, including Parkinson's. Study - Blocking Paris to preserve PGC-1α: Investigating the role of Paris in models of PGC-1α - Dr Ted Dawson, John Hopkins University School of Medicine, Boston, USA - We are delighted to say that this previously funded research has discovered several drugs that seem highly suitable to enter Parkinson’s clinical trials and decisions on precisely how to progress these compounds will be made by our expert Linked Clinical Trials committee this September. This vital research work, a huge scientific effort, will be published later this year in a major scientific journal. Investigating the mode of action of MSDC-0160 - Professor Patrik Brundin, Van Andel Research Insititute - Professor Brundin is exploring whether a novel type-2 diabetes drug (MSDC-0160) adapts mitochondrial function to see if this will be neuroprotective in two different models of Parkinson’s. He is using two different models to show clearly how this drug works, and regulators require two models to be used, so laying the groundwork for moving this into trials.Professor Brundin aims to prove that MSDC-0160 improves mitochondrial activity and stops the degenerative pathways associated with PD (preventing alpha synuclein aggregation). We expect to see the results of his work this summer and MSDC-0160 will be presented to the LCT committee in September this year with the hope that we can progress this compound towards more extensive trials. Identification of new drugs to improve neuronal energy production for treatment of PD - Dr Kambiz Alavian, Imperial College, London - Nerve cells (neurons) have a high-energy demand for transferring information as electrical signals to other cells and for storing information in the brain. Most of the energy for neurons come from mitochondria. Mitochondrial dysfunction, leading to reduced energy production, is a known contributing factor in the development of PD. Dr Alavian’s lab is focused on modifying the molecular mechanisms underlying mitochondrial energy production. The therapeutic focus of his research is to identify new ways for enhancing the efficiency of mitochondrial energy production for treatment of PD. CPT is funding Dr Alavian to conduct a drug screen using a library of 12,000 small molecules which has identified a number of possible agents to enhance mitochondrial energy production. They anticipate that, by enhancing mitochondrial metabolic efficiency, these drugs may be able to protect against neurodegeneration that is caused by several stress factors, including mutations in the PD genes. The next step is to test these agents in pre-clinical models of PD, in order to assess the safety and efficacy of each drug to see if any could be progressed to trial, via CPT’s LCT programme. Mitochondrial piRNAs: Role in PD Pathogenesis and Novel Targets for Therapeutic Intervention - Professor Matthew Wood and Sabrina M. Heman-Ackah (researcher) - Oxford University - Using induced pluripotent stem cells (iPSCs which are patient-derived skin cells that have been reprogrammed to become dopamine neurons) and treating these neurons with PD-causing toxins, we have identified a new class of small non-coding RNAs, not previously linked to Parkinson’s. Small non-coding RNAs have wide and varied biological functions in health and disease and are essential for brain development and cognition. Dr Wood’s team has identified two small non-coding RNAs, previously annotated as microRNAs (miR-1974 and miR-1978), that may in fact be piRNAs. Importantly, until now only miRNAs have been well characterised to play roles in the development of PD, no such role has been previously described for piRNAs. The discovery that piRNAs may mediate cell response to dopaminergic neurotoxins represents a novel avenue for the development of disease-modifying therapeutic interventions and finding a biomarker for Parkinson’s. Click here to download more information of this trial. Preclinical evaluation of D-PUFAs (fatty acids) as a therapeutic intervention for PD - two linked projects, by Professor Patrik Brundin, VARI, Grand Rapids, US and Professor Flint Beal, Weill Cornell Medical College, US - Investigating whether these essential fatty acids (D-PUFA's) might modify the pathology of PD in complimentary animal models in preparation for a large scale clinical trial. Oxidative stress has been linked with the death of neurons in PD. Professors Patrik Brundin and Flint Beal are working on interlinked proposals to investigate whether a very safe dietary supplement with essential fatty acids that are reinforced at the molecular level to prevent cell damage through oxidative stress might be beneficial in Parkinson’s. This work is just getting underway. To clinically evaluate this therapeutic strategy in PD patients the aim is to: Define the effect of D-PUFAs (administered as a dietary supplement) in an animal model exhibiting specific nerve cell death akin to that seen in PD. Importantly this will complement the studies in neurotoxin-based PD models, which poorly recapitulate PD neuropathology. Study whether blocking oxidative damage to lipids by supplementing with non-oxidatable fatty acids in the diet will also protect against toxicity mediated by a virally delivered human A53T alpha-synuclein delivered to the substantia nigra in an animal model. Optimise the administration of D-PUFAs and determine the levels of drug exposure and protection in relevant brain regions, and develop biomarkers of drug (D-PUFA) exposure, essential for choosing dosages in clinical trials.